High expression and activity of G6PD have been verified in cisplatin-resistant ovarian cancer (C13, SKOV3/DDP), renal cancer (ccRCC), non-small cell lung cancer (A549/DDP), and bladder cancer (T24, TCCSUP) cell lines. This evidence concerns the gene G6PD and urinary bladder cancer.